5 results match your criteria: "VA Boston Cooperative Studies Program Coordinating Center[Affiliation]"
Comparison of Gout Flares With the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-Hoc Analysis of a Randomized Multicenter Trial.
Arthritis Rheumatol
October 2024
Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
Article Synopsis
- The study aimed to compare the risk of arthritis flares when starting urate-lowering therapy (ULT) with allopurinol versus febuxostat in gout patients, focusing on the first 24 weeks of treatment.
- It analyzed data from a trial involving 940 male participants, examining flare occurrences and various predictors such as treatment type and serum urate levels.
- The findings indicated that the risk of gout flares was similar for both medications when using effective treatment strategies, with notable predictors of flare being younger age, higher initial urate levels, and the absence of tophi.
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Am J Kidney Dis
November 2024
VA Pittsburgh Health Care System, Pittsburgh, Pennsylvania; School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.
Rationale & Objective: We conducted a prespecified examination of the efficacy and safety of allopurinol and febuxostat administered using a treat-to-target strategy in trial participants with chronic kidney disease (CKD).
Study Design: Prespecified subcohort analysis of a randomized controlled trial.
Setting & Participants: A substudy of the STOP Gout Trial in participants with CKD.
Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout.
Arthritis Rheumatol
April 2024
Objective: Using trial data comparing treat-to-target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement.
Methods: Participants with gout and SU ≥6.8 mg/dL were randomized to allopurinol or febuxostat, titrated during weeks 0 to 24, and maintained weeks 25 to 48.
Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management.
NEJM Evid
March 2022
Veterans Affairs (VA) Nebraska-Western Iowa Health Care System, Omaha, Nebraska.
Background: The relative efficacy and safety of allopurinol and febuxostat when used according to current guidelines for the treatment of hyperuricemia are unknown. This double-blind noninferiority trial examined these issues.
Methods: Participants with gout and hyperuricemia (with at least 33% having stage 3 chronic kidney disease) were randomly assigned to allopurinol or febuxostat in this 72-week trial, with doses titrated to target serum urate.